U.S. Markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
22.03-0.45 (-2.00%)
At close: 4:00PM EDT
People also watch
TGTXPTLAFOLDSGYPOCUL
  • b
    ben
    ben
    Good week for Omeros as they secured anywhere from $63-71 million. Now let's get the Protocols set with the FDA and commence P3 , the lawsuits behind us and anything else that might be perceived as negative.
  • G
    GreatDayStockGuruInCA
    GreatDayStockGuruInCA
    Secondary Offering ought to have closed Friday...
  • b
    ben
    ben
    Not much support Cantor.
  • s
    siserv2001
    siserv2001
    My options expired and I made a very nice return! Now hope they make an EU partnership announcement soon and then a CE mark would be icing on the cake! Lots of studys and just waiting on results!
  • J
    Joe
    Joe
    I bought 2000 shares in the dip. Great buy opportunity!
  • A
    Anna
    Anna
    Below: @peter thanks for comment and sending OMER your IR Q?. Let me explain the kidney and how to interpret this results OMS721 is getting. Kidneys are suppose to filter waste into urine but preserve valuable protein in our blood. The more damage a kidney have the more protein it spills into the urine. The reduction in urine protein in OMS721 treated patients is remarkable, likely meaning there's some healing going on in the kidney. GFR is the rate at which the kidney is able to process fluid through it's system. The lower the GFR the greater the damage of the kidney, like a water tap giving you less and less water from corroded pipe. So a higher GFR in OMS721 tx'ed pt's is reopening the damage or corrosion of the pipes. Both remarkable. All this and no serious side effects. A game changer in IgA neph. treatment, so eventually less people need dialyses as now 10 % of people who need dialysis got there because they had IgA nephr.
  • d
    david
    david
    I remember when the price was $7 , so $22 not to hard to swallow. I still like Webs call at $75!
  • J
    J
    J
    Remember when PPS was over $25? Good times
  • M
    Matthew
    Matthew
    I'm a bit new to this, but this company is incredibly leveraged and a long way to go to make a profit. Their released med only impacts like 7,500 people. Why is this company so appealing? I haven't had a chance to dig into their other potential drugs too much yet.
  • C
    Celd
    Celd
    let us hope there is no PR today after hours
  • o
    onyxpig
    onyxpig
    3,450,000 shares were spoken for before the announcement! Count on it! All good as no borrowing (interest expense) necessary!!!! $30 by year end IMO
  • B
    Bob L.
    Bob L.
    Another great buying opportunity....bought more myself today....this is the best biotech investment out there....also AKAO, but OMER is the best right now!!!!
  • b
    ben
    ben
    Should be getting another PR today or tomorrow.
  • d
    david
    david
    How about everybody go have a couple of gin and tonics , turn off the market , get drunk and then wake up to being rich.
    It's just time-got to believe.

    BLOCKBUSTER!
  • B
    Brian
    Brian
    I agree with Duke. Anyone worrying a bit should really think whats going on. We get good news about OMS721 with the trials and we beat expectations from wallstreet on the 2Q revs. Now we only dilute 3 million shares and will get around $70+ million in cash. Not to forget the 2 tranches we have left and growing revs from Omidria. Big deal that our OS will go from 44 million to close to 48 million. Look at ALXN. Yes they have good revs right now, but they have close to 225 million shares OS! And many other small and big biotechs have 100M, 200m and 300M+. I know this is a different field, but PCLN did a reverse split several years back bringing their OS down to about 50 million. Their stock went from $35 to $2000 a shares in those several years. They have about $8 billion in revs a year, but if OMER does only 1/4 of that I think many here would be VERY happy. Its still a road ahead, but we are on our way!
  • b
    ben
    ben
    So now how soon do we announce a European partner for Omidria?
  • A
    Andreas
    Andreas
    I have to say Billy Boy, your predictions are quiet accurate. $22 close, 10% gain on news,... well done.
  • J
    J
    J

    https://seekingalpha.com/article/4099718-omeros-breakout-quarter-omidria

    Omeros: A Breakout Quarter For Omidria
    Omeros posted a strong second quarter with Omidria net sales beating expectations. The underlying growth trends look better under the surface. Looking at sell-t
    seekingalpha.com
  • T
    The Duke
    The Duke
    holding up well in a down day for biotechs and market. add here if you have cash
  • J
    J
    J
    Nothing like ending the week on such a positive note....................